PE20060654A1 - Conjugados de hormona del crecimiento humana y politilenglicol ramificado con glicerol y proceso de preparacion - Google Patents

Conjugados de hormona del crecimiento humana y politilenglicol ramificado con glicerol y proceso de preparacion

Info

Publication number: PE20060654A1
Authority: PE; Peru
Prior art keywords: growth hormone; human growth; glycerol; branched; polytilenglycol
Prior art date: 2004-08-31

Application number

PE2005000991A

Other languages

English (en)

Spanish (es)

Inventor

Rory Francis Finn

Ned Roger Siegel

Original Assignee

Pharmacia And Upjohn Company Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-31

Filing date

2005-08-26

Publication date

2006-08-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060654(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-08-26 Application filed by Pharmacia And Upjohn Company Llc filed Critical Pharmacia And Upjohn Company Llc

2006-08-12 Publication of PE20060654A1 publication Critical patent/PE20060654A1/es

Links

PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title abstract 6
102000002265 Human Growth Hormone Human genes 0.000 title abstract 4
108010000521 Human Growth Hormone Proteins 0.000 title abstract 4
239000000854 Human Growth Hormone Substances 0.000 title abstract 4
238000002360 preparation method Methods 0.000 title 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
-1 POLYETHYLENE Polymers 0.000 abstract 1
239000004698 Polyethylene Substances 0.000 abstract 1
239000000122 growth hormone Substances 0.000 abstract 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
230000000704 physical effect Effects 0.000 abstract 1
229920000573 polyethylene Polymers 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Pregnancy & Childbirth (AREA)
Cardiology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PE2005000991A 2004-08-31 2005-08-26 Conjugados de hormona del crecimiento humana y politilenglicol ramificado con glicerol y proceso de preparacion PE20060654A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US60594504P	2004-08-31	2004-08-31

Publications (1)

Publication Number	Publication Date
PE20060654A1 true PE20060654A1 (es)	2006-08-12

Family

ID=35708806

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2005000991A PE20060654A1 (es)	2004-08-31	2005-08-26	Conjugados de hormona del crecimiento humana y politilenglicol ramificado con glicerol y proceso de preparacion

Country Status (24)

Country	Link
EP (1)	EP1789092A2 (zh)
JP (1)	JP2008511610A (zh)
KR (1)	KR20070042567A (zh)
CN (1)	CN101010105A (zh)
AP (1)	AP2007003919A0 (zh)
AR (1)	AR050851A1 (zh)
AU (1)	AU2005278903A1 (zh)
BR (1)	BRPI0515118A (zh)
CA (1)	CA2577999A1 (zh)
CR (1)	CR8942A (zh)
EA (1)	EA200700380A1 (zh)
EC (1)	ECSP077281A (zh)
GT (1)	GT200500235A (zh)
IL (1)	IL181085A0 (zh)
MA (1)	MA28908B1 (zh)
MX (1)	MX2007002441A (zh)
NL (1)	NL1029828C2 (zh)
NO (1)	NO20071322L (zh)
PE (1)	PE20060654A1 (zh)
TN (1)	TNSN07078A1 (zh)
TW (1)	TW200621291A (zh)
UY (1)	UY29088A1 (zh)
WO (1)	WO2006024953A2 (zh)
ZA (1)	ZA200701802B (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7495087B2 (en)	1997-07-14	2009-02-24	Bolder Biotechnology, Inc.	Cysteine muteins in the C-D loop of human interleukin-11
BR9812267B1 (pt)	1997-07-14	2013-11-26		Hormônio de crescimento recombinante.
EP1144613B2 (en)	1999-01-14	2020-05-06	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) *	2006-03-13	2007-09-19	Siegfried Ltd.	Di-polymer protein conjugates and processes for their preparation
MX2008014358A (es) *	2006-05-12	2008-11-24	Dong A Pharm Co Ltd	Conjugado de polietilenglicol-interferon alfa.
JP2008069073A (ja) *	2006-09-12	2008-03-27	Yokohama Tlo Co Ltd	ラクトフェリン複合体及びその製造方法
KR101079993B1 (ko)	2006-11-17	2011-11-04	동아제약주식회사	폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CL2008002399A1 (es)	2007-08-16	2009-01-02	Pharmaessentia Corp	Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
WO2010011096A2 (en) *	2008-07-23	2010-01-28	Hanmi Pharmaceutical Co., Ltd.	A polypeptide complex comprising non-peptidyl polymer having three functional ends
AU2009276458B2 (en)	2008-07-31	2014-06-19	Pharmaessentia Corp.	Peptide-polymer conjugates
US8535655B2 (en)	2008-10-10	2013-09-17	Polyactiva Pty Ltd.	Biodegradable polymer—bioactive moiety conjugates
PT2355853T (pt) *	2008-10-10	2017-03-15	Polyactiva Pty Ltd	Conjugados polímero biodegradável ¿ unidade bioativa
SI2340271T1 (sl)	2008-10-10	2019-08-30	Polyactiva Pty Ltd.	Konjugati polimer-bioaktivnega sredstva
US8703717B2 (en)	2009-02-03	2014-04-22	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
WO2010091122A1 (en)	2009-02-03	2010-08-12	Amunix, Inc.	Extended recombinant polypeptides and compositions comprising same
US8680050B2 (en)	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US9849188B2 (en)	2009-06-08	2017-12-26	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
JP6086528B2 (ja)	2009-08-06	2017-03-01	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	長期のインビボ有効性を有する成長ホルモン
CN101831067A (zh) *	2010-05-31	2010-09-15	王二新	聚乙二醇脂类缀合物及其在制备药物中的应用
EP2446898A1 (en)	2010-09-30	2012-05-02	Laboratorios Del. Dr. Esteve, S.A.	Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (zh) *	2011-04-26	2013-05-08	厦门赛诺邦格生物科技有限公司	链官能化的多级支化聚乙二醇及其合成方法
WO2014110867A1 (zh) *	2013-01-17	2014-07-24	厦门赛诺邦格生物科技有限公司	一种单一官能化的支化聚乙二醇及其修饰的生物相关物质
CN104877127B (zh)	2015-06-23	2017-11-10	厦门赛诺邦格生物科技股份有限公司	一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
SI3215193T1 (sl)	2014-11-06	2024-02-29	Pharmaessentia Corporation	Dozirna shema za pegiliran interferon
JP7227633B2 (ja) *	2017-12-29	2023-02-22	エフ．ホフマン－ラロシュエージー．	Ｐｅｇ化タンパク質組成物を提供するための方法
EP3731872B1 (en)	2017-12-29	2021-11-24	F. Hoffmann-La Roche AG	Process for providing pegylated protein composition
JP7137625B2 (ja) *	2017-12-29	2022-09-14	エフ．ホフマン－ラロシュアーゲー	Ｐｅｇ化タンパク質組成物を提供するための方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2147192A (en) *	1991-06-28	1993-01-25	Genentech Inc.	Method of stimulating immune response using growth hormone
JP3092531B2 (ja) *	1996-11-05	2000-09-25	日本油脂株式会社	コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
BR9812267B1 (pt) *	1997-07-14	2013-11-26		Hormônio de crescimento recombinante.
JP3921781B2 (ja) *	1998-02-12	2007-05-30	日本油脂株式会社	カルボキシル基含有ポリオキシアルキレン化合物
EP1144613B2 (en) *	1999-01-14	2020-05-06	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
IL162031A0 (en) *	2001-11-20	2005-11-20	Pharmacia Corp	Chemically-modified human growth hormone conjugates
AP2005003246A0 (en) *	2002-09-09	2005-03-31	Nektar Therapeutics Al Corp	Water-soluble polymer alkanals
JP4412461B2 (ja) *	2002-11-20	2010-02-10	日油株式会社	修飾された生体関連物質、その製造方法および中間体
WO2004060406A2 (en) *	2002-12-31	2004-07-22	Nektar Therapeutics Al, Corporation	Polymeric reagents comprising a ketone or a related functional group
TR201907313T4 (tr) *	2003-05-23	2019-06-21	Nektar Therapeutics	İki PEG zinciri içeren PEG türevleri.

2005
- 2005-08-25 EA EA200700380A patent/EA200700380A1/ru unknown
- 2005-08-25 CA CA002577999A patent/CA2577999A1/en not_active Abandoned
- 2005-08-25 AU AU2005278903A patent/AU2005278903A1/en not_active Abandoned
- 2005-08-25 CN CNA2005800291171A patent/CN101010105A/zh active Pending
- 2005-08-25 MX MX2007002441A patent/MX2007002441A/es unknown
- 2005-08-25 BR BRPI0515118-0A patent/BRPI0515118A/pt not_active IP Right Cessation
- 2005-08-25 AP AP2007003919A patent/AP2007003919A0/xx unknown
- 2005-08-25 EP EP05784225A patent/EP1789092A2/en not_active Withdrawn
- 2005-08-25 WO PCT/IB2005/002939 patent/WO2006024953A2/en active Application Filing
- 2005-08-25 KR KR1020077004912A patent/KR20070042567A/ko not_active Application Discontinuation
- 2005-08-25 JP JP2007529040A patent/JP2008511610A/ja active Pending
- 2005-08-26 PE PE2005000991A patent/PE20060654A1/es not_active Application Discontinuation
- 2005-08-29 AR ARP050103612A patent/AR050851A1/es unknown
- 2005-08-29 UY UY29088A patent/UY29088A1/es not_active Application Discontinuation
- 2005-08-30 NL NL1029828A patent/NL1029828C2/nl not_active IP Right Cessation
- 2005-08-30 TW TW094129583A patent/TW200621291A/zh unknown
- 2005-08-30 GT GT200500235A patent/GT200500235A/es unknown
2007
- 2007-01-31 IL IL181085A patent/IL181085A0/en unknown
- 2007-02-26 CR CR8942A patent/CR8942A/es not_active Application Discontinuation
- 2007-02-27 TN TNP2007000078A patent/TNSN07078A1/fr unknown
- 2007-02-27 EC EC2007007281A patent/ECSP077281A/es unknown
- 2007-02-28 MA MA29724A patent/MA28908B1/fr unknown
- 2007-02-28 ZA ZA200701802A patent/ZA200701802B/xx unknown
- 2007-03-09 NO NO20071322A patent/NO20071322L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ECSP077281A (es)	2007-03-29
MX2007002441A (es)	2007-05-04
IL181085A0 (en)	2007-07-04
EA200700380A1 (ru)	2007-10-26
GT200500235A (es)	2006-03-21
ZA200701802B (en)	2008-08-27
NL1029828C2 (nl)	2006-10-20
NL1029828A1 (nl)	2006-03-01
WO2006024953A3 (en)	2007-01-18
JP2008511610A (ja)	2008-04-17
CA2577999A1 (en)	2006-03-09
NO20071322L (no)	2007-05-29
KR20070042567A (ko)	2007-04-23
EP1789092A2 (en)	2007-05-30
MA28908B1 (fr)	2007-10-01
BRPI0515118A (pt)	2008-07-01
CR8942A (es)	2007-08-16
AP2007003919A0 (en)	2007-02-28
AU2005278903A1 (en)	2006-03-09
TW200621291A (en)	2006-07-01
CN101010105A (zh)	2007-08-01
WO2006024953A2 (en)	2006-03-09
AR050851A1 (es)	2006-11-29
UY29088A1 (es)	2006-03-31
TNSN07078A1 (fr)	2008-06-02

Legal Events

Date	Code	Title	Description
2009-03-16	FD	Application declared void or lapsed

Publication	Publication Date	Title
PE20060654A1 (es)	2006-08-12	Conjugados de hormona del crecimiento humana y politilenglicol ramificado con glicerol y proceso de preparacion
PE20081503A1 (es)	2008-12-07	Miembros de union para il-6
AR047062A1 (es)	2006-01-04	Conjugados portadores de peptidos inmunogenicos a beta y metodos para producirlos
NO2016007I2 (no)	2016-05-10	Susoktokog
CY1122134T1 (el)	2020-11-25	Συνθεση για χρηση στη θεραπευτικη αντιμετωπιση της γαστρεντερικης δυσκινησιας
BRPI0410731A (pt)	2006-06-20	composto, composição farmacêutica, métodos para agonizar o receptor mc4, para tratar obesidade, para tratar diabetes melito e para tratar disfunção sexual masculina e/ou feminina em um mamìfero, e, uso de um composto
CY1112831T1 (el)	2016-02-10	Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh
PE20090711A1 (es)	2009-07-15	Region constante de anticuerpo mutante
WO2006020722A3 (en)	2007-02-08	Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
GEP20063860B (en)	2006-06-26	Chemically-modified human growth hormone conjugates
RS54215B1 (en)	2015-12-31	COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
EA200802166A1 (ru)	2009-06-30	Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
DE60004172D1 (de)	2003-09-04	Gcsf konjugate
AR045016A1 (es)	2005-10-12	Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades.
MX338134B (es)	2016-04-01	Formas salinas de adicion de acido de conjugados de polimeros-farmaco y metodos de alcoxilacion.
CY1106723T1 (el)	2012-05-23	Ν-τελικα μονοπεγυλιωμενα συζευγματα ανθρωπινης αυξητικης ορμονης, διεργασιες για την παρασκευη τους και μεθοδοι χρησης αυτων
BRPI0406172A (pt)	2006-03-28	processo e dispositivo para a implantação minimamente invasiva de biomaterial
AR060152A1 (es)	2008-05-28	Agentes herbicidas en forma de dispersiones que contienen diflufenican y flurtamona
CR11174A (es)	2010-03-23	Composicion, metodo y preparacion del acido biliar sintetico
DE60325377D1 (de)	2009-01-29	Motilidverbindungen
BRPI0408946A (pt)	2006-04-04	material biologicamente ativo conjugado com polìmero biocompatìvel com complexo 1:1, seu processo de preparação e composição farmacêutica compreendendo o mesmo
DE602005015855D1 (de)	2009-09-17	Verfahren zur herstellung von immunogenen konjugaten
CL2008002275A1 (es)	2009-08-07	Proceso para producir 3-cloro-n-(3-cloro-5-trifluorometil-2-piridil)-a,a,a-trifluoro-2,6-dinitro-p-toluidina usando un solvente del tipo cetonas, nitrilos, esteres y eteres en presencia de 20 a 40% p/p de agua.
PE20141549A1 (es)	2014-10-25	VARIANTES DE CRIg MADURAS POR AFINIDAD
UA93254C2 (ru)	2011-01-25	Способ получения препарата инсулина для перорального применения